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Abstract
Background: Peri-implant crevicular fluid (PICF) contains calprotectin and NTx, which are markers for inflammation
and bone resorption, respectively. The aims of this pilot study were to compare calprotectin and NTx levels in PICF
from implant sites with or without peri-implant diseases and to evaluate the usefulness of calprotectin and NTx as
diagnostic markers for peri-implant diseases.
Methods: Thirty-five patients with dental implants participated in this pilot study. PICF samples were collected from
peri-implant disease sites (n = 40) and non-diseased (healthy) sites (n = 34) after clinical indicators including probing
depth (PD), bleeding on probing (BOP), gingival index (GI), and bone loss (BL) rate were investigated. Calprotectin
and NTx amounts in PICF were measured using their respective ELISA kits and then compared between diseased
and healthy samples. The relationship between PICF calprotectin or NTx levels and clinical indicator levels was
investigated. A receiver operating characteristic (ROC) curve analysis of calprotectin and NTx was performed to
predict peri-implant diseases.
Results: Calprotectin and NTx levels in PICF were significantly higher from peri-implant disease sites than from
healthy sites. PICF calprotectin amounts correlated with PD, and its levels were significantly higher in the GI-1 and
GI-2 groups than in the GI-0 group. PICF NTx amounts correlated with PD and the BL rate. ROC curves indicated
that PICF calprotectin and NTx are useful biomarkers for peri-implant diseases.
Conclusions: Calprotectin and NTx in PICF have potential as biomarkers for the diagnosis of peri-implant diseases.
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Background
Dental treatments with implants are now being widely per-
formed due to advances in the development of surgical
procedures for dental implants and prosthodontics. How-
ever, the incidence of peri-implant diseases has been
increasing with implant placement [1], and thus, the early
detection of these diseases is important for maintaining
dental implants. Peri-implant diseases with inflammation
and the destruction of peri-implant tissues have mainly
been classified into peri-implantitis with the resorption of
alveolar bone around osseointegrated dental implants and
peri-implant mucositis without pathological bone resorp-
tion [2]. Peri-implant diseases are diagnosed by clinical in-
dicators including probing depth (PD), bleeding on
probing (BOP), suppuration, the mobility of an implant,
and radiographic bone loss (BL) [3, 4]. Clinical indicators
for a diagnosis of peri-implant diseases are similar to the
diagnostic indicators for periodontal diseases of natural
teeth. However, the measurement of PD using a dental
probe is more difficult around dental implants than around
natural teeth because peri-implant tissues have less
attached gingiva compared with periodontal tissue, and im-
plant structures and prosthetic superstructures sometimes
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prevent a probing [3, 5]. BL of 2–3 mm on radiographs
has been used as a diagnostic standard in cumulative inter-
ceptive supportive therapy (CIST) [6]; however, difficulties
are associated with obtaining accurate information on
slight BL on radiographs in conventional X-ray examina-
tions. The prevalence of peri-implant mucositis and
peri-implantitis was previously reported to be between 19
and 65% and between 1 and 47%, respectively [1, 7], and
showed a wide range because case definition of
peri-implant diseases was different among those studies in
which peri-implant diseases were diagnosed using clinical
indicators. These reports suggest that the case definition
with the diagnosis of peri-implant diseases using clinical
indicators is not sufficiently accurate or clear to evaluate
pathological conditions.
The diagnosis of peri-implant diseases using biomarkers
in peri-implant crevicular fluid (PICF) has recently been
examined and may be more accurate than that of clinical
indicators to evaluate inflammation and the degradation
of tissue surrounding dental implants [4, 7, 8]. PICF con-
tains similar components to gingival crevicular fluid
(GCF), namely pro-inflammatory cytokines such as
interleukin-1β (IL-1β) and tumor necrosis factor-α
(TNF-α), enzymes including aspartate aminotransferase
(AST) and collagenase-2 (matrix metalloproteinase-8
(MMP-8)), and bone-related proteins such as cross-linked
C-telopeptide of type I collagen (ICTP) and receptor acti-
vator of nuclear factor-κB (NF-κB) ligand (RANKL) [9–
13]. These factors and proteins in PICF and GCF are
regarded as diagnostic biomarkers for peri-implant dis-
eases as well as periodontal diseases.
Calprotectin (S100A8/S100A9) is an inflammation-related
protein that is produced in leukocytes, macrophages/mono-
cytes, and epithelial cells, and its level increases in several
inflammatory diseases including ulcerative colitis, rheuma-
toid arthritis, and cystic fibrosis [14, 15]. Calprotectin was
previously detected in GCF, and its level was significantly
higher in GCF from periodontal disease sites than in that
from healthy non-diseased sites [16, 17]. Furthermore, GCF
calprotectin levels correlated with clinical indicator levels,
such as PD, GI, and BOP [17, 18], and was shown to predict
periodontal disease activity [19]. These findings indicate that
calprotectin is a useful inflammatory biomarker for peri-
odontal diseases. Calprotectin was also detected in PICF,
but its levels in PICF samples from healthy and
peri-implant disease sites were not compared [20].
Cross-linked N-telopeptide of type I collagen (NTx) is a
product of bone type I collagen degradation by cathepsin K
in osteoclasts, is released into blood and urine, and is a spe-
cific biomarker of bone resorption [21–23]. NTx levels have
been shown to increase in the blood and urine of patients
with osteoporosis, hyperparathyroidism, and bone metasta-
sis of cancer and are used as a diagnostic marker for these
bone metabolism diseases [23, 24]. GCF contains NTx, and
significant differences were not detected in its levels in
GCF between healthy and periodontitis sites [25–27]. In
contrast, Aruna [28] examined NTx in GCF samples from
periodontitis sites and did not detect NTx in GCF from
healthy sites. Although Friedmann et al. [20] measured
NTx amounts in PICF and GCF, its levels in PICF did not
correlated with changes of alveolar bone levels.
This pilot study aims to investigate whether calprotec-
tin and NTx levels in PICF reflect inflammation and al-
veolar BL in peri-implant tissues, respectively, and also if
these proteins are useful biomarkers for the diagnosis of
peri-implant diseases.
Methods
Patients and clinical examinations
The present clinical study was approved by the Ethics
Committees of Tokushima University Hospital (nos.
2368 and 2719) in accordance with the Helsinki Declar-
ation of 2013 and performed from November 2016 to
August 2017. Patients who received dental implants
from 3 to 9 years ago, had healthy or diseased implants
with peri-implant diseases, and visited at Tokushima
University Hospital for the maintenance of dental im-
plants and treatment were recruited for the present clin-
ical study. Thirty-five patients (10 males and 25 females;
aged 68.7 ± 6.5 years) gave written informed consent
after receiving an explanation of this study (Table 1).
Participants with healthy and diseased dental implants
did not have any systemic inflammatory diseases or a
history of antibiotic therapy within 3 months. PD, BOP,
and gingival index (GI) were examined as clinical indica-
tors after the collection of PICF. GI scores were evalu-
ated according to modifications of the standard of Löe
and Silness [29]. The BL rate of alveolar bone was
assessed on radiographic films according to modifica-
tions of Schei et al.’s method [30]. Diseased sites with
peri-implant diseases were defined as periodontal sites
with PD ≥ 3 mm, BOP negative or positive, and GI score
Table 1 Characteristics of participants and examining sites
Participants
Number of participants 35
Gender (male/female) 10:25
Age (years) 68.7 ± 6.5
Examining sites Healthy Diseased
Number of PICF samples 34 40
PD (mm) 2.32 ± 0.58 4.70 ± 1.36†
Gingival index 0.0 ± 0.0 1.5 ± 0.5†
BOP-positive rate (%) 0.0 ± 0.0 40.0 ± 15.2*
Bone loss rate (%) 19.7 ± 9.8 42.7 ± 18.0†
*P < 0.01 and †P < 0.001 vs healthy group
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≥ 1. Healthy implant sites were defined as sites with PD
< 3 mm, BOP negative, and GI score = 0.
PICF sampling and sample preparation
PICF samples were collected from peri-implant sites
using sterile paper strips according to a modified pro-
cedure of our previous method [31]. Briefly, PICF sam-
pling sites were isolated with cotton rolls, supra-gingival
plaque was removed, and sites were then very gently
air-dried. Periopaper® (Oraflow Inc., NY, USA) was gen-
tly inserted into a peri-implant crevice and held for 30 s.
The volume of PICF was measured using a Periotron®
8000 (Harco Electronics, Winnipeg, MB, Canada). Paper
strips containing blood and pus were not used in the
present study. PICF in the paper strip was extracted in
100 μl of phosphate-buffered saline (pH = 7.4) contain-
ing 0.2 μM phenylmethylsulfonyl fluoride by centrifuga-
tion and used in ELISA for calprotectin and NTx.
Protein determination by ELISA
Calprotectin in PICF samples was determined using Cal-
protectin Human ELISA kit® (Hycult Biotech, PB Uden, the
Netherlands) according to the instruction manual. Briefly,
the extracted PICF solution was diluted to 100–200-fold
using dilution buffer provided in the kit. The diluted PICF
solution was added to wells coated with an antibody of hu-
man calprotectin and incubated at room temperature for
1 h. After washing the wells, a biotinylated anti-calprotectin
antibody was added and incubated at room temperature for
1 h. An immune complex in the wells was reacted with a
streptavidin-peroxidase conjugate for 1 h and further incu-
bated with 3,3′,5,5′-tetramethylbenzidine (TMB) for
15 min in the dark. After stopping the reaction using a stop
solution, the absorbance of the reacting solution in wells
was determined using a microplate reader at 450 nm.
NTx in PICF samples was measured using Human
NTx-I ELISA kit® (LifeSpan Biosciences Inc., Seattle, WA,
USA) according to the instruction manual. Briefly, ex-
tracted PICF samples were added to wells and incubated
at 37 °C for 90 min. A biotinylated anti-NTx antibody was
added to the wells containing PICF sample solution and
incubated at 37 °C for 1 h with gentle agitation. After
washing the wells, HRP conjugate was added, incubated at
37 °C for 30 min, and then reacted with TMB substrate so-
lution at 37 °C for 15 min. After stopping the reaction, the
absorbance of the reacting solution was determined using
at 450 nm. The concentrations of calprotectin and NTx
were expressed as nanograms per microliter of PICF.
Statistical analysis
Differences in PD, GI, the BL rate, calprotectin levels, and
NTx levels between healthy and diseased groups were sta-
tistically analyzed by the Mann-Whitney U test. Differ-
ences in the BOP-positive rate between healthy and
diseased groups were statistically evaluated using Fisher’s
exact test. Difference in calprotectin amounts among the
GI score 0, 1, and 2 groups were analyzed by the
Mann-Whitney U test. The relationships between PD and
calprotectin or NTx amounts and between the BL rate
and NTx amount were analyzed by Spearman’s rank cor-
relation test. Receiver operating characteristic (ROC)
curves was constructed for calprotectin and NTx amounts
in the healthy and diseased groups. Data were analyzed
using statistical analysis software (SPSS version 20, IBM,
Chicago, IL, USA). P values less than 0.05 were considered
to indicate significance.
Results
Characteristics of PICF samples and sites of PICF
collection
Thirty-four of PICF samples were collected from healthy
peri-implant sites and forty samples from diseased sites
(Table 1). The mean PD in diseased sites was 4.70 mm,
which was significantly deeper than that of healthy sites
(2.32 mm). The mean GI score of diseased sites was 1.5,
which was significantly higher than that of healthy sites. A
significant difference was observed in the BOP-positive
rate between diseased and healthy sites (diseased = 40.0 vs
healthy = 0.0; P < 0.01). Furthermore, the mean BL rate of
peri-implant disease sites was 42.7%, which was approxi-
mately 2.2-fold that of healthy sites (19.7%).
Comparison of calprotectin and NTx levels between
diseased and healthy sites
Mean calprotectin amounts in PICF samples from dis-
eased and healthy sites were 171.9 and 40.1 ng per site,
respectively (Fig. 1a), and their mean concentrations
were 231.7 and 113.2 ng/μl PICF, respectively (Fig. 1b).
Calprotectin amounts and concentrations in the diseased
group were significantly higher than those in the healthy
group by approximately 4.3-fold and 2.1-fold, respect-
ively (healthy vs diseased; P < 0.01).
NTx amounts in PICF samples from healthy sites
ranged between 0.03 and 14.34 ng per site, while those in
samples from diseased sites were between 0.85 and
16.38 ng per site (Fig. 2a). Mean NTx amounts were 6.16
and 2.94 ng per site in PICF samples from the diseased
and healthy groups, respectively, while the mean concen-
trations of NTx in the diseased and healthy groups were
9.27 and 6.62 ng/μl PICF, respectively (Fig. 2b). NTx levels
in PICF samples were significantly higher from diseased
sites than from healthy sites (healthy vs diseased: NTx
amount P < 0.01, NTx concentration P < 0.05).
Relationship between calprotectin amounts in PICF and
clinical indicators
The PD range in all PICF sampling sites was 1–8 mm and
calprotectin amounts ranged between 0.1 and 534.1 ng per
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site (Fig. 3a). A positive correlation was observed between
calprotectin amounts in PICF samples and PD (ρ = 0.709,
P < 0.001). The relationship between calprotectin amounts
in PICF samples and GI scores was investigated (Fig. 3b).
The median of calprotectin amounts in PICF samples were
36.8, 110.3, and 159.3 ng at GI-0, GI-1, and GI-2 sites,
respectively. Calprotectin amounts in PICF samples
from sites with GI-1 and GI-2 were significantly
higher than those from sites with GI-0 (GI-0 vs GI-1
or GI-2, P < 0.001); however, no significant difference
was noted in calprotectin amounts between GI-1 and
GI-2.
Relationship between NTx amounts in PICF and PD or BL
rate
NTx amounts in PICF samples correlated with PD at PICF
sampling sites (ρ = 0.434, P < 0.001, Fig. 4a). The BL rate
in healthy sites ranged between 6.9 and 41.8%, while that
in diseased sites was between 7.7 and 80.0% (Fig. 4b). A
positive correlation was observed between NTx amounts
and the BL rate (ρ = 0.570, P < 0.001).
ROC analysis for cutoff values of calprotectin and NTx
amounts in PICF
ROC curves for calprotectin and NTx levels in PICF were
plotted in order to predict peri-implant diseases. The area
under the ROC curve (AUC) for calprotectin amounts
was 0.964 (95% CI = 0.913–0.996, P < 0.001) and the cutoff
value was 60.4 ng per site, with a sensitivity of 92.5% and
specificity of 90.9% (Fig. 5a). The AUC for NTx amounts
was 0.784 (95% CI = 0.672–0.891, P < 0.001) and the cutoff
value was 1.88 ng per site, with a sensitivity of 82.5% and
specificity of 63.6% (Fig. 5b).
Fig. 1 Comparison of calprotectin levels in PICF. PICF samples were collected from peri-implant disease sites (n = 40, diseased) and non-diseased
sites (n = 34, healthy). Calprotectin amounts (a) were measured by ELISA, and its concentration (b) was normalized by the volume of PICF.
Horizontal bars show the mean values of each group. *P < 0.01
Fig. 2 Comparison of NTx levels in PICF. NTx amounts (a) in PICF samples from peri-implant disease sites (n = 40, diseased) and non-diseased
sites (n = 34, healthy) were measured by ELISA, and its concentration (b) was normalized by the volume of PICF. Horizontal bars show the mean
values of each group. ‡P < 0.05, *P < 0.01
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Discussion
Diagnostic studies on peri-implant diseases using bio-
markers in PICF have been performing because clinical in-
dicators do not necessarily lead to an accurate evaluation of
peri-implant diseases [5, 7, 8, 32]. Calprotectin levels were
significantly higher in periodontitis GCF than in healthy
GCF, and thus, calprotectin is regarded as a useful inflam-
matory marker for periodontal diseases [16, 17, 19]. Calpro-
tectin amounts in PICF were measured, and its levels did
not significantly change between 2 and 3 years after the
functional loading of dental implants [20]. However, calpro-
tectin levels in PICF samples from sites with and without
peri-implant diseases have not yet been investigated. The
present study demonstrated that calprotectin amounts and
concentrations in PICF samples were significantly higher
from diseased sites than from healthy sites, and a positive
association was observed between calprotectin levels and
clinical indicators such as PD and GI scores. This result for
peri-implant diseases was similar to previous findings ob-
tained in diagnostic studies on periodontal diseases [16, 33].
A significant difference was noted in calprotectin amounts
between GI-0 group and GI-1 or GI-2 group, suggesting
that PICF calprotectin indicates initial, weak inflammation
in peri-implant diseases because calprotectin is mainly
existed in leukocytes that more express at early stage of in-
flammation and acute inflammation [14, 15]. In contrast,
there was a little difference of the median of calprotectin
level between the GI-1 and GI-2 groups, but not significant
difference, supposing that calprotectin amounts may reach
to almost the maximum level at inflammation sites with
GI-1 and GI-2. The ability of some biomarkers including
pro-inflammatory cytokines, inflammation-related factors,
and proteolytic enzymes to diagnose peri-implant diseases
has been examined [5, 7, 8, 32]. IL-1β, IL-6, and PGE2 levels
Fig. 3 Relationship between PICF calprotectin amounts and PD or GI scores. a The relationship between PICF calprotectin amounts and PD was
evaluated in PICF samples from peri-implant disease and healthy groups (n = 74, ρ = 0.709, P < 0.001). b Relationship between PICF calprotectin
amounts and GI scores. Calprotectin amounts in PICF samples from sites with GI-0 (n = 34), GI-1 (n = 20), and GI-2 (n = 20) were statistically
analyzed. Horizontal bars show the median of each group. †P < 0.001
Fig. 4 Correlation between NTx amounts and PD or BL rates. a The correlation between PICF NTx amounts and PD was evaluated in PICF
samples from peri-implant disease and healthy groups (n = 74, ρ = 0.434, P < 0.001). b The correlation between PICF NTx amounts and BL rates
(%) was evaluated in PICF samples from peri-implant disease and healthy groups (n = 74, ρ = 0.570, P < 0.001)
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in PICF were significantly higher from peri-implantitis sites
than from healthy implant sites [10, 34, 35]. However,
Aboyoussef et al. [36] and Melo et al. [37] showed no sig-
nificant differences in IL-1β, IL-6, and PGE2 levels between
peri-implantitis and healthy groups. These reports indicate
an opposite result, which IL-1β, IL-6, and PGE2 are reliable
markers to detect peri-implant diseases or not. In con-
trast, PICF calprotectin levels showed very high sensi-
tivity (92.5%) and specificity (90.9%) for a diagnosis of
peri-implant diseases when the cutoff value was 60.4 ng
per site. The sensitivity and specificity of PICF calpro-
tectin were higher than those of AST activity, which
was higher in PICF from peri-implant diseases sites
than from healthy sites, with a sensitivity = 81% and
specificity = 74% [12]. MMP-8 levels were previously
reported to be increased in PICF from sites with
peri-implantitis [11], and MMP-8 levels in PICF from
peri-implant disease sites correlated with GI scores (ρ
= 0.772, P < 0.001) [38]. The correlation observed be-
tween PICF calprotectin levels and GI scores in the
present study (ρ = 0.744, P < 0.001, data not shown) was
similar to the relationship between MMP-8 levels and
GI scores.
We did not classify peri-implant diseases into
peri-implant mucositis and peri-implantitis in this pilot
study. Peri-implant mucositis does not show BL, whereas
peri-implantitis shows BL of more than 2.5 or 3 mm on
intra-oral radiographs [39, 40]. Figuero et al. [2] introduced
plural diagnostic criteria for peri-implant mucositis and
peri-implantitis. Rakic et al. [5] defined peri-implantitis as a
PD of more than 5 mm, BOP positive, and BL of at least
two threads of implant. Furthermore, Sanz et al. [41] pro-
posed their opinion for the radiographic assessment of al-
veolar bone in peri-implant treatment. However, difficulties
are associated with accurately measuring 2–3 mm of alveo-
lar BL on a radiograph taken by a regular method and
assessing BL levels by implant threads when implant spe-
cies differ. We evaluated BL around dental implants using
Schei et al.’s method [30], which has been used to evaluate
BL rate in periodontal diseases. The mean BL rate was sig-
nificantly higher at peri-implant disease site than at healthy
sites without inflammation and deep PD. Therefore, we did
not distinguish peri-implant mucositis and peri-implantitis
that were diagnosed by measuring bone level on radiograph
in the present pilot study. Biomarkers for BL may be more
accurate than clinical BL indicators because PICF NTx
amounts were found to correlate with BL rates determined
by Schei et al.’s method (ρ = 0.570, P < 0.001). Biomarkers
for bone metabolism in PICF and clinical, radiological
assessment of bone level may accurately diagnose
peri-implant mucositis and peri-implantitis.
Bone-related proteins including ICTP, osteocalcin
(OCN), and RANKL have been studied as BL biomarkers
in peri-implantitis. ICTP, a cross-linked C-telopeptide of
type I collagen, is a marker for bone degradation, and its
levels in PICF were significantly higher from
peri-implantitis sites than from healthy sites [9, 42]. How-
ever, Tümer et al. [13] did not detect a significant differ-
ence in PICF ICTP levels between peri-implantitis and
healthy sites. RANKL is a main mediator of osteoclast for-
mation and associated with bone resorption [43]. Soluble
RANKL (sRANKL) concentrations in PICF were signifi-
cantly higher from peri-implantitis sites than from healthy
implant sites (P < 0.01), and its levels correlated with clin-
ical indicators such as PD (ρ = 0.309, P = 0.034) and BOP
(ρ = 0.327, P = 0.024) [44]. In the present study, NTx
amounts and concentrations showed similar significant dif-
ferences to sRANKL between the peri-implant disease and
healthy groups (amount: P < 0.01, concentration: P < 0.05),
and a stronger correlation was observed between NTx
amounts and PD (ρ = 0.434, P < 0.001). In contrast, Arikan
et al. [9] showed that sRANKL concentrations in PICF
Fig. 5 ROC analyses of PICF calprotectin and NTx to predict peri-implant diseases. PICF samples were collected from sites with and without peri-
implant diseases (n = 74). Calprotectin (a) and NTx (b) amounts in PICF samples were subjected to ROC curve analysis. AUC values for calprotectin
and NTx amounts were 0.964 (95% CI = 0.913–0.996, P < 0.001) and 0.784 (95% CI = 0.672–0.891, P < 0.001), respectively, when cutoff values were
60.4 ng/site (arrow in a) and 1.88 ng/site (arrow in b)
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were significantly higher in healthy groups, while Sarlati et
al. [45] reported no significant difference in PICF sRANKL
concentrations among healthy, peri-implant mucositis, and
peri-implantitis groups. OCN is a major non-collagenous
protein in bone and is associated with bone metabolism
[46]. The mean OCN concentration in PICF from
peri-implantitis sites was approximately 1.5-fold that of
healthy groups [13], and this finding was similar to the re-
sult for NTx in PICF. Although OCN levels in PICF sam-
ples were significantly higher from peri-implant mucositis
sites without BL than from healthy sites, OCN levels in
PICF from peri-implantitis with BL was not significantly
different from those in PICF from healthy and peri-implant
mucositis sites [47]. These conflicting findings do not ne-
cessarily suggest that ICTP, sRANKL, and OCN are reliable
biomarkers for alveolar BL. Few studies showed a relation-
ship between the PICF levels of bone-related markers and
those of clinical indicators for alveolar BL. NTx levels in
GCF samples were significantly higher from periodontitis
sites than from healthy sites [28]; however, the relationship
between NTx levels in PICF or GCF and BL levels has not
yet been investigated. NTx in PICF may be a reliable bio-
marker for evaluating BL in peri-implantitis because PICF
NTx levels correlated with the BL rate as well as PD and
had high sensitivity and specificity for predicting
peri-implant diseases.
Treatments for peri-implant diseases are selected by
CIST [6], in which clinical indicators including PD, BOP,
implant mobility, and BL on radiographs are used to diag-
nose peri-implant diseases. However, these clinical indica-
tors are not considered to be sufficiently accurate or
objective for the diagnosis of peri-implant diseases. Bio-
markers in PICF contribute to the diagnosis of peri-implant
diseases by clinical indicators and may provide a reliable
diagnosis of onset, progression, and prognosis of disease as
well as the selection of treatments. This pilot study suggests
that calprotectin and NTx in PICF may be useful bio-
markers for the diagnosis of peri-implant diseases, and fu-
ture study using a large number of PICF samples will
support the results obtained herein.
Conclusions
Calprotectin and NTx in PICF are markers of inflamma-
tion and bone resorption in peri-implant tissues and may
be useful diagnostic markers for peri-implant diseases.
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